Skip to main content

Association of a genetic variant in the angiopoietin-like protein 4 gene with metabolic syndrome



Metabolic syndrome (MetS) is characterized by a clustering of cardiovascular risk factors that include: abdominal obesity, dyslipidemia, hypertension and glucose intolerance. Angiopoietin-like protein 4 (ANGPTL4) is a circulating peptide that is an inhibitor of lipoprotein lipase, a key enzyme in lipid metabolism. The objective of this study was to investigate the association of ANGPTL4 gene variants (E40K) with fasting serum triglyceride levels and with cardiovascular risk factors, that included the presence of MetS in 817 subjects recruited from the Mashhad stroke and heart Atherosclerosis Disorders (MASHAD) cohort Study.


ANGPTL4 genotypes were determined using a TaqMan genotyping based real time PCR method. The association of the genetic variant with the risk of metabolic syndrome and its relationship with lipid profile were determined.


The frequency of GG, GA and AA genotypes were 96.9, 2.7 and 0.4% in individuals with MetS, and 78.8, 20.8, 0.4%, in those without MetS. The GA genotype of the rs116843064 polymorphism was associated with a lower risk for MetS (e.g., OR in Codominant genetic model: 0.14, 95% CI: (0.06–0.33), p < 0.0001). Subject with an A allele had a higher risk for MetS (OR: 6.72, 95% CI: (3.05–14.82), p < 0.0001). There was a significant difference in fasted lipid profiles across the genotypes for ANGPTL4. Carriers of the AG genotype had higher levels of serum HDL-cholesterol (HDL-C) and lower TG, compared to the GG homozygotes genotype.


The G allele at the rs116843064 polymorphic locus of the ANGPTL4 gene was associated with a lower prevalence of MetS.

Peer Review reports


Metabolic syndrome is increasing globally, and is important because of its association with increased cardiovascular disease (CVD) risk [1]. It affects about 20 to 25% of the adult population [2]. MetS is characterised by a clustering of CVD risk factors that include: high blood pressure, dyslipidemia, impaired glucose tolerance and abdominal obesity [1]. MetS is associated with an increased risk of CVD and diabetes mellitus [3, 4]. MetS is also associated with other co-morbidities including fatty liver [5, 6], asthma [7, 8] and some cancers [9,10,11].

The development of MetS depends on environmental (e.g., physical inactivity, diet, gender, age) and genetic factors [12,13,14,15,16]. Chronic stress has also been shown to increase the risk of MetS [17]. Angiopoietin–like proteins are secreted proteins [18] that have major role in the metabolism of energy, lipid and glucose [19, 20]. Angiopoietin–like proteins 4 (ANGPTL4) is a circulating peptide which inhibits lipoprotein lipase [21] and hence influences the metabolism of triglyceride-rich lipoproteins [22, 23].

Long periods of fasting, low calorie diet and a diet high in fat and energy increase plasma free fatty acid concentrations and levels of ANGPTL4, most probably by activation of PPARs in liver and adipose tissue [24, 25]. ANGPTL4 is abundantly expressed in the liver, placenta and adipose tissues [26]. T266 M (rs1044250) and E40K(rs116843064) are two variants of the ANGPTL4 gene [21]. E40K is a fairly rare variant that is found in about 3% of the population of European ancestry [27] and is associated with lower serum LDL-cholesterol and triglyceride and higher HDL-cholesterol [27, 28].

However, other reports have suggested that the serum ANGPTL4 is positively associated with serum triglycerides in individuals with MetS [29]. These variants are also associated with CVD. Abid et al. found that in CAD subjects the GA genotype for rs116843064 polymorphism there was an increased CVD risk [21]. It has also been reported that serum ANGPTL4 is lower in subjects with type 2 diabetes. However no associations were found in subjects with MetS or obesity [30], although subjects with MetS have higher levels of plasma ANGPTL4 [31]. A study in knock-out mice observed that Angptl4-deficient mice have altered lipid metabolism and also smaller atherosclerotic lesions [32]. The primary aim of this current study was to evaluate the association between the rs116843064 gene variant of the ANGPTL4 gene and the presence of MetS.


Study population

The study population comprised 260 with, and 557 individuals without MetS, who were recruited from the Mashhad Stroke and Heart Atherosclerosis Disorder (MASHAD) cohort study. They were recruited through a cluster-randomized-recruitment in 2007–2008, as described previously [33, 34]. MetS was defined according to the International-Diabetes-Federation (IDF) criteria including waist circumference > 94 cm in men and > 80 cm in women along with at least two of the other criteria for MetS, such as fasting serum triglycerides> 150 mg/dl, HDL-C < 40 mg/dl in men or < 50 mg/dl in women, BP > 130/85 mmHg and fasting glucose> 100 mg/dl. In the current study subjects with CAD, stroke and peripheral arterial disease were excluded.

Informed written consent was obtained from all individuals, and the study protocol was approved by the Ethics Committee of the MUMS. All participants were able to read and understand and were willing to provide written, informed consent.

General entry and exclusion criteria for this study and public specifications of the sample participants, including marital status, occupational status, drug use and biochemical measurements were obtained as previously described (32–33).

Anthropometric and biochemical measurements

Anthropometric parameters containing weight (kg), height (m), waist circumference (cm), hip circumference (cm), waist/hip (cm), BMI (kg/m2), systolic blood pressure (mmHg) and diastolic blood pressure (mm Hg) were determined for all participant as previously described [34]. To evaluated BMI body weight (kg) divided by squared height in meters (m2) was used. Biochemical parameters including fasted serum triglyceride(mg/dl), cholesterol (mg/dl), HDL-C(mg/dl), fasting blood glucose (mg/dl), serum Hs-CRP (mg/dl) and uric acid were measured as explained previously [35].


Genomic DNA was extracted from peripheral blood using a QIAamp-DNAMini-Kit (Qiagen, SanDiego, CA) and the manufacturer’s protocol. Using the NanoDrop®-1000-Detector (NanoDrop-Technologies, Wilmington, USA) the purity and concentration of DNAs were evaluated. The genotyping of the ANGPTL4 rs116843064 polymorphism was performed using Taqman®-probes-based assay. The PCR reaction was performed in a total volume of 12.5 μl through 10 ng DNA in TaqMan® Universal Master Mix with particular primes and probes (Applied Biosystems Foster City, CA). ABIPRISM tools with SDS-version 2.0 software has been used to examine the content of allelic samples.

Statistical analyses

The analysis of the data was performed using SPSS 22 software (SPSS Inc., Chicago, IL). A Kolmogorove Smirnov test was untaked to determine the normality of the data within groups. The genotype and allele frequencies of the ANGPTL4 rs116843064 polymorphism were determined for analysis for the Hardy–Weinberg equilibrium (HWE) through Pearson χ distribution. Kruskal-Wallis and Mann-Whitney U tests, or ANOVA and t tests were used to evaluate the differences between groups. The relationship between the risk of MetS with GG and GA genotypes, versus the AA genotype under recessive genetic model, were investigated through various genetic models. MetS risk was expressed as the odds ratio (OR) and its corresponding 95% confidence interval (CI). The analyses were two-sided and statistical significance was set at P < .05.


General characteristic of subjects

Anthropometrics and biochemical characteristic of MetS and healthy subjects are presented in Table 1. The mean age of the individuals with MetS and non-MetS subjects were 49.53 ± 7.64 and 49.59 ± 8.54, respectively. BMI, waist circumference, weight, hip circumference, waist/hip, systolic blood pressure and diastolic blood pressure, fasting serum triglycerides, uric acid and Hs-CRP were higher than in the control group (p < 0.05). Also fasting blood glucose was higher in MetS patients but there was no significant difference between the two groups.

Table 1 Anthropometrics and biochemical data of MetS and healthy group

However height, serum cholesterol, HDL and LDL were higher in the non-MetS group (Table 1).

Clinical characteristic of populations

We have found that the genotype frequency of GG, GA and AA were 96.9, 2.7 and 0.4% in MetS group and 78.8, 20.8, 0.4%, respectively in those without MetS (Table 2). The distribution of genotypes and allele frequencies of ANGPTL4 gene rs116843064 polymorphism, were in Hardy-Weinberg equilibrium (HWE) (P < 0.05).

Table 2 Distribution of genotypes and allele frequencies and their association with metabolic syndrome

Association of the genetic variant with MetS

The distribution of the ANGPTL4 gene rs116843064 polymorphism genotypes were investigated in genetic various models (Table 2). These data indicated that the GA genotype of the rs116843064 polymorphism in Codominant model was associated with a lower risk for MetS (e.g., OR in Codominant genetic model: 0.14, 95% CI: (0.06–0.33), p < 0.0001). Also subjects with an A allele had a higher risk for MetS (OR: 6.72, 95% CI: (3.05–14.82), p < 0.0001).

Association between rs116843064 polymorphism and lipid profile

The relationship between the ANGPTL4 gene rs116843064 polymorphism and serum fasted TG and HDL level in total population and non-MetS group is presented in Table 3. This shows that the carriers of GA genotype had a higher level of serum HDL and lower serum TG, compared with the GG homozygotes, with the wild genotype (p < 0.0001).

Table 3 Association between SNP and serum TG and HDL level


Multiple studies have revealed that metabolic syndrome is a risk factor for diabetes mellitus, hypertension, pro-inflammatory state, central adiposity, dyslipidemia and high concentrations of ANGPTL4 [18, 36]. A large number of studies have shown that the E40K variant within the ANGPTL4 gene is linked with significant differences in serum triglycerides and HDL cholesterol. This relationship can be explained at least in part by its function in the inhibition the activity of lipoprotein lipase and stimulates adipose tissue lipolysis and relates to dyslipidemia [23, 24]. A meta-analysis comprising 49,549 subjects has shown that the rs116843064 SNP is a missense variant in ANGPTL4 gene that is involved in determining triglyceride concentrations [37]. Genotypes of SNPs in 1654 individuals of Chinese Han population verified the potential function of the ANGPTL4 variants on circulating lipid levels and diseases that are related to atherosclerosis [38].

Free fatty acids through the lipid-sensing peroxisome proliferator-activated receptors (PPARs) play a main role in the expression regulation of ANGPTL4 [18]. On the other hand a significant correlation is found between the ANGPTL4 concentration and FFA levels in subjects with type 2 diabetes mellitus (T2DM) compared to healthy individuals [39].

Sadeghabadi et al., have reported an association of plasma levels of ANGPTL4 and expression of PPARγ gene with metabolic characteristics in obese children and adolescents. Although both of PPARγ gene expression and levels of ANGPTL4 were decreased in individuals with obesity, significant association were not found in obese children with insulin resistance as compared to those without insulin resistance and also in obese children with or without metabolic syndrome [40]. Although the association of ANGPTL4 variant and risk of MetS has been inconsistent, the results of some recent investigations are in line with the findings of the current study. The results of the current study indicated that carriers of the A allele (AA or GA genotypes) of the ANGPTL4 gene have higher levels of HDL but lower TG levels, compared to those with GG homozygote genotype. Moreover the GA genotype was associated with reduced risk of MetS. Some other studies showed that the E40K variant was linked with lower serum TG and higher HDL-cholesterol [27, 28]. The Atherosclerosis Risk in Communities study and the Copenhagen City Heart Study demonstrated that the E40K variant was associated with a lower levels of TG and LDL cholesterol but higher levels of HDL cholesterol [28]. In line with these findings, Dewey et al. showed that carriers of the E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and also a lower risk of coronary artery disease compared with non-carriers. The authors of this study found that the presence of the E40K variant was associated with a 19% lower risk of coronary artery disease than for E40 homozygotes [41]. Experiments on the regulation of Angptl4 expression within arterial macrophages have shown that formation of foam cells is suppressed by Angptl4 expression and leads to a lower risk of atherosclerosis. Moreover, overexpression of Angptl4 may play a crucial role in lipid metabolism [42]. Abid et al. speculated that the variants of ANGPTL4 may be associated with the reduced fasting triglyceride levels and consequently these variants may reduce the risk of cardiovascular disease [21]. A prospective study conducted by Folsom and colleagues revealed that individuals with E40K variant possess reduced genetic risk for coronary heart disease [43]. Stejskal et al., demonstrated that in individuals with MetS the concentration of serum ANGPTL4 was directly associated with serum TG [29]. Smart-Halajko et al., showed an inverse association between serum ANGPTL4 and HDL-cholesterol and could not find any significant associations between coronary heart disease and the levels of serum ANGPTL4 [44]. An investigation of the association between ANGPTL4 levels and metabolic parameters in a population based study, concentrations of ANGPTL4 were found to be positively related to the metabolic syndrome, and plasma ANGPTL4 concentrations were inversely related to LDL-C and HDL-C, but positively associated with serum triglycerides [45]. Other study showed that polymorphism within the ANGPTL4 gene is not related to metabolic components in white subjects [46].

Miida et al. observed that in individuals with MetS, serum ANGPTL4 was directly associated with serum triglycerides [31]. Muendlein et al., have shown that the variants of ANGPTL4 and the plasma levels of ANGPTL4 may have a potential role in the prediction of cardiovascular events and also the characteristics of the MetS were linked with the levels of serum ANGPTL4 [26]. However, Dlouha et al., did not find a relationship between the rs116843064 ANGPTL4 gene polymorphism and risk of acute coronary syndrome in a Czech population [39]. The results of a cohort study by Staiger et al., demonstrated that fasting FFA and adipose tissue lipolysis were directly associated with plasma ANGPTL4 [36]. The results of various studies indicate that plasma levels of ANGPTL4 were higher in MetS and T2DM compared to the control group [18, 30].


In summary our results supports a significant relationship between the rs116843064 genetic polymorphism within the ANGPTL4 gene with the presence of MetS and lipid profile.



Angiopoietin-like protein 4


Body mass index


Coronary artery disease


Cardiovascular disease


Diastolic/systolic blood pressure


Fasting blood glucose


Hip circumference


High density lipoprotein


High sensitivity C reactive protein


Hardy-Weinberg equilibrium


International Diabetes Federation


Inter quartile range


Low density lipoprotein


Mashhad Stroke and Heart Atherosclerosis Disorder


Mashhad University of Medical Science


Polymerase Chain Reaction


Standard deviation


single nucleotide polymorphism


Type 2 Diabetes Mellitus




Waist circumference


  1. 1.

    Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005;366(9491):1059–62.

    Article  Google Scholar 

  2. 2.

    Ranasinghe P, et al. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017;17(1):101.

    CAS  Article  Google Scholar 

  3. 3.

    Meigs JB, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906–12.

    CAS  Article  Google Scholar 

  4. 4.

    Felizola SJ. Ursolic acid in experimental models and human subjects: Potential as an anti-obesity/overweight treatment? Cancer. 2015;1:2.

    Google Scholar 

  5. 5.

    DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14(3):173–94.

    CAS  Article  Google Scholar 

  6. 6.

    Marchesini G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844–50.

    CAS  Article  Google Scholar 

  7. 7.

    V Garmendia J, et al. Metabolic syndrome and asthma. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(1):60–6.

    Article  Google Scholar 

  8. 8.

    Brumpton BM, et al. Metabolic syndrome and incidence of asthma in adults: the HUNT study. Eur Respir J. 2013;42(6):1495–502.

    CAS  Article  Google Scholar 

  9. 9.

    Bjørge T, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Prev Biomark. 2010;19(7):1737–45.

    Article  Google Scholar 

  10. 10.

    Borena W, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J Cancer. 2012;131(1):193–200.

    CAS  Article  Google Scholar 

  11. 11.

    Stocks T, et al. Metabolic risk score and cancer risk: pooled analysis of seven cohorts. Int J Epidemiol. 2015;44(4):1353–63.

    Article  Google Scholar 

  12. 12.

    Pollex RL, Hegele RA. Genetic determinants of the metabolic syndrome. Nat Rev Cardiol. 2006;3(9):482.

    CAS  Article  Google Scholar 

  13. 13.

    Bouchard C. Genetics and the metabolic syndrome. Int J Obes Relat Metab Disord. 1995;19:S52.

    PubMed  Google Scholar 

  14. 14.

    Edwardson CL, et al. Association of sedentary behaviour with metabolic syndrome: a meta-analysis. PLoS One. 2012;7(4):e34916.

    CAS  Article  Google Scholar 

  15. 15.

    Katzmarzyk PT, et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE family study. Med Sci Sports Exerc. 2003;35(10):1703–9.

    CAS  Article  Google Scholar 

  16. 16.

    Malik VS, et al. Sugar-sweetened beverages and risk of metabolic syndrome and type 2 diabetes: a meta-analysis. Diabetes Care. 2010;33(11):2477–83.

    Article  Google Scholar 

  17. 17.

    Gohil BC, et al. Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity. CNS Spectrums. 2001;6(7):581–9.

    CAS  Article  Google Scholar 

  18. 18.

    Tjeerdema N, et al. Inflammation increases plasma angiopoietin-like protein 4 in patients with the metabolic syndrome and type 2 diabetes. BMJ Open Diabetes Res Care. 2014;2(1):e000034.

    Article  Google Scholar 

  19. 19.

    Hato T, Tabata M, Oike Y. The role of angiopoietin-like proteins in angiogenesis and metabolism. Trends Cardiovasc Med. 2008;18(1):6–14.

    CAS  Article  Google Scholar 

  20. 20.

    Oike Y, et al. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy. Trends Mol Med. 2005;11(10):473–9.

    CAS  Article  Google Scholar 

  21. 21.

    Abid K, et al. ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels and predicts cardiovascular disease risk in type 2 diabetic Tunisian population. Lipids Health Dis. 2016;15(1):63.

    Article  Google Scholar 

  22. 22.

    Desai U, et al. Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci. 2007;104(28):11766–71.

    CAS  Article  Google Scholar 

  23. 23.

    Ge H, et al. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J Biol Chem. 2004;279(3):2038–45.

    CAS  Article  Google Scholar 

  24. 24.

    Jonker JT, et al. Dietary modulation of plasma angiopoietin-like protein 4 concentrations in healthy volunteers and in patients with type 2 diabetes. Am J Clin Nutr. 2013;97(2):255–60.

    CAS  Article  Google Scholar 

  25. 25.

    Kersten S, et al. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated free fatty acids. Arterioscler Thromb Vasc Biol. 2009;29(6):969–74.

    CAS  Article  Google Scholar 

  26. 26.

    Muendlein A, et al. Angiopoietin-like protein 4 significantly predicts future cardiovascular events in coronary patients. Atherosclerosis. 2014;237(2):632–8.

    CAS  Article  Google Scholar 

  27. 27.

    Romeo S, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet. 2007;39(4):513.

    CAS  Article  Google Scholar 

  28. 28.

    Talmud PJ, et al. ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc Biol. 2008;28(12):2319–25.

    CAS  Article  Google Scholar 

  29. 29.

    Stejskal D, et al. Angiopoietin-like protein 4: development, analytical characterization, and clinical testing of a new ELISA. Gen Physiol Biophys. 2008;27(1):59–63.

    CAS  PubMed  Google Scholar 

  30. 30.

    Xu A, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipidemia and hepatic steatosis in mice. Proc Natl Acad Sci. 2005;102(17):6086–91.

    CAS  Article  Google Scholar 

  31. 31.

    Miida T, Hirayama S. Impacts of angiopoietin-like proteins on lipoprotein metabolism and cardiovascular events. Curr Opin Lipidol. 2010;21(1):70–5.

    CAS  Article  Google Scholar 

  32. 32.

    Adachi H, et al. Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis. Biochem Biophys Res Commun. 2009;379(4):806–11.

    CAS  Article  Google Scholar 

  33. 33.

    Ghayour-Mobarhan M, et al. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015;60(5):561–72.

    Article  Google Scholar 

  34. 34.

    Zomorrodian D, et al. Metabolic syndrome components as markers to prognosticate the risk of developing chronic kidney disease: evidence-based study with 6492 individuals. J Epidemiol Community Health. 2015.

    Article  Google Scholar 

  35. 35.

    Motamed S, et al. Micronutrient intake and the presence of the metabolic syndrome. N Am J Med Sci. 2013;5(6):377.

    Article  Google Scholar 

  36. 36.

    Staiger H, et al. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator–activated receptor (PPAR)-δ and is of metabolic relevance in humans. Diabetes. 2009;58(3):579–89.

    CAS  Article  Google Scholar 

  37. 37.

    van Leeuwen EM, et al. Meta-analysis of 49 549 individuals imputed with the 1000 genomes project reveals an exonic damaging variant in ANGPTL4 determining fasting TG levels. J Med Genet. 2016;53(7):441–9.

    Article  Google Scholar 

  38. 38.

    Dewey FE, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123–33.

    CAS  Article  Google Scholar 

  39. 39.

    Dlouhá D, et al. Variants within HNF1α and ANGPTL4 genes and acute coronary syndrome in Czech population. The GENDEMIP study. Neuroendocrinol Lett. 2012;33(supplement 2):13–6.

    PubMed  Google Scholar 

  40. 40.

    Leininger MT, Portocarrero CP, Houseknecht KL. Peroxisome proliferator-activated receptor γ1 expression in porcine white blood cells: dynamic regulation with acute endotoxemia. Biochem Biophys Res Commun. 1999;263(3):749–53.

    CAS  Article  Google Scholar 

  41. 41.

    Yang Q, et al. ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses. Nutr Metabol. 2018;15(1):70.

    Article  Google Scholar 

  42. 42.

    Georgiadi A, Wang Y, Stienstra R, Tjeerdema N, Janssen A, Stalenhoef A, van der Vliet JA, de Roos A, Tamsma JT, Smit JW, Tan NS. Overexpression of angiopoietin-like protein 4 protects against atherosclerosis development. Arterioscler Thromb Vasc Biol. 2013;33(7):1529–37.

    CAS  Article  Google Scholar 

  43. 43.

    Folsom AR, et al. Variation in ANGPTL4 and risk of coronary heart disease: the atherosclerosis risk in communities study. Metabolism. 2008;57(11):1591–6.

    CAS  Article  Google Scholar 

  44. 44.

    Smart-Halajko MC, et al. The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk. Arterioscler Thromb Vasc Biol. 2010;30(11):2277–82.

    CAS  Article  Google Scholar 

  45. 45.

    Mehta N, et al. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits. Arterioscler Thromb Vasc Biol. 2014;34(5):1057–63.

    CAS  Article  Google Scholar 

  46. 46.

    Staiger H, et al. Genetic variation within the ANGPTL4 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus. Metabolism. 2008;57(5):637–43.

    CAS  Article  Google Scholar 

Download references


We would like to thank the National Institutes for Medical Research Development (NIMAD) of Tehran and Mashhad University of Medical Sciences Research Council for their financial supports.


Research reported in this publication was supported by Elite Researcher Grant Committee under award number [958675] from the National Institutes for Medical Research Development (NIMAD), Tehran, Iran. The funder involved in study design, data collection .

Availability of data and materials

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Author information




We declare that we contributed significantly towards the research study i.e., Data analysis was performed by M T, H E and H Gh. Conception and interpretation of results was performed by M T, H E, and H Gh. A A, J Kh-Kh and A R-M, designed the presented idea. Drafting the article performed by S Kh-Kh and developed by S S. Revising the paper critically for important intellectual content was carried out by G A. F, S Kh-Kh, and S S and finally the article was approved by G A. F, M Gh-M, A A. The project supervised by H E and A A. Also, All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Amir Avan or Habibollah Esmaily.

Ethics declarations

Ethics approval and consent to participate

Informed consent was obtained from all subjects using protocols approved by the Ethics Committee of the Mashhad University of Medical Sciences. All participants were able to read and understand and were willing to provide written, informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kharazmi-Khorassani, S., Kharazmi-Khorassani, J., Rastegar-Moghadam, A. et al. Association of a genetic variant in the angiopoietin-like protein 4 gene with metabolic syndrome. BMC Med Genet 20, 97 (2019).

Download citation


  • Metabolic syndrome
  • rs116843064